Author:
Svedberg Anna,Gréen Henrik,Vikström Anders,Lundeberg Joakim,Vikingsson Svante
Funder
Swedish Research Council
Swedish Cancer Society
Medical Research Council of Southeast Sweden
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference24 articles.
1. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase;Moyer;Cancer Res.,1997
2. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies;Hidalgo;J. Clin. Oncol.,2001
3. Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature;Petit-Jean;Ther. Drug Monit.,2014
4. Therapeutic drug monitoring in cancer—are we missing a trick?;Bardin;Eur. J. Cancer,2014
5. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21;Clark;Clin. Lung Cancer,2006
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献